After a courtship of more than six months, Shire won over the fellow drug maker Baxalta on Monday in a deal valued at about $31 billion. The combination would create a giant in the treatment of rare diseases.
Baxalta, which was spun out of Baxter International, generates a large portion of its sales from Advate, a drug for hemophilia. The company also has a portfolio of plasma therapies and treatments for immune diseases.
19:39 $1M '100 percent Swiss Made' watch made of real Swiss cheese16
21:52 Netflix nears 94 million subscribers 10 years after streaming launch18
16:50 Goldman Sachs, Citigroup earnings confirm Trump effect on banks18
18:21 Mark Zuckerberg takes the stand in $2 billion lawsuit claiming Oculus theft8